Compounded semaglutide in 2026: is it still legal and safe?
A precise read on a moving regulatory picture.
TL;DR
- Compounded semaglutide is permitted in narrow, patient-specific circumstances under federal compounding law.
- The 2024 FDA shortage delisting changed the rules for 503B outsourcing facilities. 503A patient-specific compounding follows a different framework.
- Litigation, warning letters, and pharmacy enforcement have all shaped the access picture in 2026. Read the rules, not the marketing.
What it is
Compounded semaglutide is a version of the GLP-1 (glucagon-like peptide-1) receptor agonist semaglutide that is prepared by a state-licensed compounding pharmacy from an FDA-approved active pharmaceutical ingredient. The branded products — Ozempic, Wegovy, Rybelsus — are FDA-approved. The compounded version itself is not FDA-approved; it is prepared under the federal compounding framework set out in the Food, Drug, and Cosmetic Act.
How it works
Think of compounding like two bakeries with different rules. A 503A bakery (in plain English: a state-licensed pharmacy compounding for an individual patient with a prescription) follows one set of rules, with patient-specific orders at the center. A 503B bakery (an outsourcing facility under FDA oversight) follows a stricter rule that historically allowed broader compounding only when a drug was on the FDA shortage list. When semaglutide came off the shortage list, the 503B doorway narrowed sharply. The 503A doorway remained open under its patient-specific rules.
Who asks about it
People come to this topic because they want to know whether a telehealth provider that prescribed compounded semaglutide last year can still do so this year, and whether the version they receive is legal under federal law. They also come because they have read about lawsuits and warning letters and want to know what those actually mean for access.
What the research says
The FDA published its semaglutide shortage update and resolution timeline on the Drug Shortages page (FDA, 2024). FDA’s broader compounding Q&A explains the different roles of 503A and 503B facilities and the limits of compounded products against approved alternatives (FDA Compounding Q&A, 2024). About 4 in 10 FDA warning letters in the March 2026 telehealth wave cited compounded GLP-1 marketing or dispensing as the basis for action.
What to know before considering it
Compounded GLP-1 products are the subject of ongoing litigation, including Novo Nordisk v. Hims & Hers, Feb 2026. Compounded medications are not FDA-approved. Side effects of GLP-1 therapies are common and may include nausea, injection-site reactions, and gastrointestinal symptoms. Any GLP-1 therapy — branded or compounded — requires a valid prescription following a licensed clinician evaluation.
The Halftime POV
We respect the rules and we say so plainly. Compounding for an individual patient under a valid prescription, prepared by a state-licensed 503A pharmacy from an FDA-approved active ingredient, remains a defined pathway. Mass-market GLP-1 advertising has run ahead of the rules. Halftime Health prescribes through licensed clinicians, in states where our partner physicians are credentialed, and inside the framework as it actually reads in 2026.
Related reading:
- Compounded semaglutide: what it is and how it differs from branded
- Novo Nordisk v Hims & Hers: the compounded GLP-1 case
- 503A vs 503B compounding pharmacies explained
FAQ
Q: Is compounded semaglutide still legal in 2026? A: Compounding semaglutide is permitted in narrow circumstances under FDA compounding rules — including documented clinical need or shortage status. Routine compounding outside those rules is enforcement-priority territory.
Q: What changed after the FDA shortage delisting? A: When semaglutide was delisted from the FDA shortage list, 503B outsourcing facilities lost the broad shortage-based exception. 503A pharmacies operate under different rules, and patient-specific prescribing remains the relevant pathway.
Q: What does the Novo Nordisk v Hims litigation mean? A: The Feb 2026 case challenges marketing and dispensing practices around compounded GLP-1. It does not by itself ban compounding, but it raises legal exposure for telehealth platforms that overstep the patient-specific compounding rules.
Disclaimer
This article is educational and is not medical advice. Compounded GLP-1 medications are prepared by state-licensed 503A compounding pharmacies from FDA-approved active pharmaceutical ingredients and are not themselves FDA-approved. GLP-1 therapies are available only with a valid prescription following a licensed clinician evaluation. Compounded GLP-1 products are the subject of ongoing litigation (Novo Nordisk v. Hims & Hers, Feb 2026). Clinical outcomes depend on individual factors including baseline health, adherence, diet, and physical activity. Individual results vary. Side effects are common and may include nausea, injection-site reactions, and gastrointestinal symptoms. Halftime Health is launching soon — join the waitlist to get updates.
Get updates
Halftime Health is launching soon. We’ll share what we learn along the way — the research, the regulations, the real-world trade-offs. Join the waitlist and we’ll email you when we’re live.
Sources
- FDA. Medications containing semaglutide marketed for type 2 diabetes or weight loss. (FDA Drug Shortages, 2024)
- FDA. Human Drug Compounding — Q&A. (FDA, 2024)
